drugset / Trial / NCT04621409

LEAP2 on Postprandial Glucose Metabolism and Food Intake

NCT04621409 ↗

Phase 0 Completed 20 enrolled University Hospital, Gentofte, Copenhagen
RandomizedCrossoverDouble-blindTreatment

Summary

The study aim to delineate the effects of the naturally occurring peptide liver-enriched antimicrobial peptide 2 (LEAP-2) on postprandial glucose metabolism and food intake in healthy volunteers. The overall objective is to investigate the physiological importance of LEAP-2 in healthy subjects.

Timeline

Start
2020-11-17
Primary completion
2021-02-18
Completion
2021-02-18

Drugs

EvaluationDrugModalityDoseRoute
Subject LEAP2 Peptide — Intravenous

Indications